Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool May 29, 2007 Brian Lawler	The One Development-Stage Drug Stock to Own Now With such a low level of Remoxy sales baked into its share price, and minimal clinical trial risk, investors who consider Pain Therapeutics around today's share price won't be hurting in the long run, if you assume there will be a viable market for abuse-resistant opioids.
The Motley Fool June 15, 2011 Brian Orelli	Investors Need a Peephole Into FDA Offices Cell Therapeutics is gung ho about its resubmission, but investors only get one side of the story.
The Motley Fool October 26, 2010 Travis Hoium	ARIAD Pharmaceuticals Shares Plunged: What You Need to Know A day after shares pop, the company announced a stock offering at $3.70 per share, and shares drop.
The Motley Fool October 12, 2010 Brian Orelli	Clinical Trial Positive! Shares Just Barely A story about expectations. Seattle Genetics is two for two in recent weeks.
The Motley Fool October 19, 2010 Travis Hoium	Cell Therapeutics Shares Popped: What You Need to Know Cell Therapeutics shares jumped 11% today on news the company received a positive opinion for Pixuvri.
The Motley Fool December 31, 2011 Brian Orelli	3 Stock-Moving Binary Events to Watch in 2012 Binary events, FDA decisions, and clinical trial results, are the lifeblood -- and death wish -- of the biotech industry. Here are three to watch in 2012.
The Motley Fool March 30, 2010 Brian Orelli	Invest in This Space at Your Own Risk Lung cancer is a tough foe for drugmakers.
The Motley Fool September 28, 2011 Brian Orelli	One Step Closer to an FDA Decision Cell Therapeutics is still risky, though.
The Motley Fool January 3, 2011 Brian Orelli	Clinical Trial Results Fail to Inspire Inspire Pharma gets cut in half after a cystic fibrosis trial failure.
The Motley Fool May 23, 2008 Brian Orelli	Progenics' Mixed Trial Data Progenics Pharmaceuticals and marketing partner Wyeth release both positive and negative clinical trial data.
The Motley Fool April 26, 2004 Alyce Lomax	Genentech's Lucky Day Genentech and OSI Pharmaceuticals jump in today's trading session after favorable trial results for a cancer drug.
The Motley Fool July 29, 2011 Sean Williams	Another Day, Another Loss For Cell Therapeutics Cell Therapeutics is giving shareholders that sinking feeling.
The Motley Fool January 3, 2011 Travis Hoium	Inspire Pharmaceuticals Shares Plunged: What You Need to Know The new trading year came in with a loud thud for Inspire Pharmaceuticals when its stock fell 58% this morning.
The Motley Fool July 23, 2007 Brian Lawler	Progenics Gets Back In the Game Being the first approved to market an oral compound to treat one of the more painful side effects from opioid use will be a boon to whichever drugmaker can reach this goal. With the competitior Adolor looking more likely to be out of this race, Progenics is in the pole position once again.
The Motley Fool November 10, 2006 Brian Lawler	Dendreon Pending Approval A lot is riding on what the FDA will say about the small pharma's drug for prostate cancer. Investors, take note.
The Motley Fool February 16, 2010 Brian Orelli	For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward.
The Motley Fool April 2, 2007 Brian Lawler	Pain Therapeutics Pares Shares The small drugmaker announces a share buyback.
The Motley Fool September 6, 2007 Brian Lawler	Encysive, Please Stop Its failure to acquiesce to the FDA's request means the competition is going forward as this drugmaker's product stays stagnant. Investors, take note.
The Motley Fool May 18, 2009 Brian Orelli	Is There Life After 600% Returns? Just because a drug company gets a massive increase in the stock price after a positive clinical trial or an FDA approval, that doesn't mean all the growth is completely factored into the stock price.
The Motley Fool November 11, 2010 Brian Orelli	ATTRACTing Clinical Trial Failure Let's not make it a habit, Novartis. Novartis is dropping development of lung-cancer treatment ASA404 after a second failed phase 3 trial.
The Motley Fool October 14, 2010 Matt Koppenheffer	Cell Therapeutics' Shares Popped: What You Need to Know Shares of biopharma specialist Cell Therapeutics leapt more than 16% today on huge volume.
The Motley Fool August 2, 2007 Brian Lawler	United Therapeutics Unites R and D The drugmaker quietly beats the market while vying for its share of customers. Investors, take note.
The Motley Fool March 8, 2010 Brian Orelli	Really? A 59% Share Price Jump for That? Justified or not, InterMune skyrockets ahead of an FDA panel meeting.
The Motley Fool July 30, 2010 Anand Chokkavelu	5 Stocks to Consider Before Buying Pfizer If you like Pfizer, you may like these five insurance and medical stocks better.
The Motley Fool June 15, 2005 Brian Gorman	Cell Therapeutics' Gamble The biotech company's struggles are far from over. Without an approved drug on the market or the certainty of FDA clearance, the firm won't have an easy time finding investors.
Chemistry World November 12, 2013 Dinsa Sachan	Rough patch for India's clinical trial industry The Indian clinical trial industry is beset by uncertainty. Campaigners have petitioned the courts claiming that drug companies are exploiting poor people and this has led to more than 100 trials being put on hold.
The Motley Fool May 4, 2011 Brian Orelli	Cell Therapeutics: Denied but Not Rejected Cell Therapeutics' ball may be headed for the end zone, but the FDA has an eight-foot free safety ready to bat it down.
The Motley Fool February 26, 2007 Brian Lawler	Waiting on AtheroGenics The results might be positive for this pharma, but don't bet on it. Investors, take note.
The Motley Fool June 27, 2011 Arundhati Parmar	St. Jude Medical's Migraine Treatment: Good for Europe, but Not the U.S.? St. Jude won't comment on whether the company plans to do a second clinical trial or whether it is confident it will win approval from the FDA without it.
The Motley Fool October 18, 2011 Evan Niu	Halozyme Therapeutics Shares Surged: What You Need to Know Shares of Halozyme Therapeutics are surging by as much as 22.5% today on news that, together with partner Roche Holding, the company has reported positive results from a trial study regarding one of its drugs.
The Motley Fool May 28, 2009 Robert Steyer	Fighting an Incurable Disease United Therapeutics battles drug giants in a specialized blood-pressure treatment arena.
The Motley Fool January 29, 2008 Brian Lawler	Acorda Rides the Wave Acorda Therapeutics announces positive clinical trial data on its lead multiple sclerosis drug.
The Motley Fool September 15, 2010 Brian Orelli	Cell Therapeutics Goes for Broke If Cell Therapeutics can't get new funding soon, long-term consequences may be the least of its worries; time on the clock looks to be running out.
Bio-IT World August 2005 Ellen H. Julian	Tech Expertise Singles Out Outsourcers Biopharmaceutical companies are flocking to consultants, outsourcers, and staffing firms to help with discrete clinical trial processes to gain access to advanced technologies and reduce the drain on already-scarce IT resources.
The Motley Fool July 7, 2010 Dave Mock	A Big Upgrade for Novartis This bullish call comes from more than just one analyst.
The Motley Fool May 2, 2007 Brian Lawler	Progenics' Intriguing Study Results The development-stage drugmaker released clinical trial results for one of its compounds. Investors, take note.
The Motley Fool January 28, 2009 Brian Orelli	M&A Off the Beaten Path CV Theraputics gets courted.
The Motley Fool May 2, 2007 Mike Havrilla	Heads Up, Biotech Investors: Chapter 2 Get to know the timing of major catalysts for stocks that may be on your biotech watch list.
The Motley Fool July 27, 2010 Brian Orelli	Brilinta? I Think Not. AstraZeneca's new blood thinner is far from brilliant.
The Motley Fool May 2, 2007 Brian Lawler	Another Free Quarter of Pain If the Remoxy abuse-resistant platform technology produces more positive clinical trial results later in the year, investors should have plenty to cheer about.
The Motley Fool November 28, 2008 Brian Orelli	The FDA's Killing Bug Killers Unfortunately for Johnson & Johnson and Swiss drugmaker Basilea Pharmaceutica, the FDA appears a little reluctant to take some of the data for the drugmakers' antibiotic ceftobiprole at face value.
The Motley Fool March 30, 2005 David Nierengarten	Soothing Results, But Pain for Investors Pain Therapeutics delivers again but its stock barely budged. What gives?
The Motley Fool May 27, 2011 Brian Orelli	What Kind of Phase 2 Drug Can You Get for $5 Million? Cell Therapeutics issues a press release saying the company has identified a potential acquisition opportunity that is a phase II drug candidate.
The Motley Fool March 21, 2007 Brian Lawler	New Indication for Pain Pain Therapeutics brings a new drug into the clinic. When drug companies attempt to bring new drugs that are outside of their core competencies to market, investors always need to be wary.
The Motley Fool March 1, 2007 Brian Lawler	Know Your Drug Stock ABCs: Part 2 Investing in the pharmaceutical and biotechnology industries can be difficult. Here are terms investors should know to better understand how the clinical trial process involved with bringing a drug to market works.
The Motley Fool December 31, 2011 David Williamson	2011 Review: Cell Therapeutics After starting the year at a split-adjusted $2.22 a share, Cell Therapeutics stock lost almost 50% of its value by the end of December, closing at $1.16. How did we get here?
The Motley Fool May 7, 2007 Mike Havrilla	Critical Therapeutics' Juncture With approval likely, the real challenge will be selling an asthma drug once it's on the market. While shares may get a brief bounce, this may not be a case of "if you approve it, they will prescribe."
The Motley Fool December 23, 2011 Selena Maranjian	3 Biotech Stocks That Had a Bad 2011 It's a volatile business, and these biotechs got the short end of the stick.
The Motley Fool April 29, 2011 Brian Orelli	Oral Multiple Sclerosis Drugs Heat Up Watch out Novartis and Gilenya.
The Motley Fool June 15, 2010 Brian Orelli	Just Enough to Give Investors Hope Hitting a secondary endpoint means all is not lost for Onyx's lung cancer drug.